# Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

> **NCT00588523** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- CNS Cancer
- CNS BRAIN

## Interventions

- **DRUG:** temozolomide followed by high dose busulfan and thiotepa

## Key facts

- **NCT ID:** NCT00588523
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588523, "Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00588523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*